Investing.com - Eagle Pharm reported on Monday third quarter earnings that missed analysts' forecasts and revenue that fell short of expectations.
Eagle Pharm announced earnings per share of $1.12 on revenue of $65.9M. Analysts polled by Investing.com anticipated EPS of $1.85 on revenue of $85.49M.
Eagle Pharm shares are down 28% from the beginning of the year, still down 34.45% from its 52 week high of $56.43 set on December 21, 2021.
Eagle Pharm shares gained 17.24% in intra-day trade following the report.
Eagle Pharm follows other major Healthcare sector earnings this month
Eagle Pharm's report follows an earnings beat by UnitedHealth on October 14, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on October 18 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar